Loading clinical trials...
Loading clinical trials...
A Phase 1b Multicenter Pre-Surgical Study to Evaluate Immune Biomarker Modulation in Response to Motolimod (VTX-2337) in Combination With Nivolumab in Subjects With Resectable Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Conditions
Interventions
VTX-2337
Nivolumab
Locations
12
United States
Local Institution - 112
Birmingham, Alabama, United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Boston University
Boston, Massachusetts, United States
Local Institution - 116
Boston, Massachusetts, United States
Local Institution - 102
St Louis, Missouri, United States
Washington University
St Louis, Missouri, United States
Start Date
July 3, 2019
Primary Completion Date
January 24, 2022
Completion Date
January 24, 2022
Last Updated
February 24, 2023
NCT04099290
NCT06912087
NCT04564989
NCT05955924
NCT03485209
NCT03833167
Lead Sponsor
Celgene
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions